HCID 22503186, 화합물 → HCID 22503420, 화합물
반응식
Cl.[CH2:2]([N:4]1[CH2:9][CH2:8][N:7]([C:10]2[C:19]3[C:14](=[CH:15][CH:16]=[CH:17][CH:18]=3)[CH:13]=[C:12]([C:20]3[CH:25]=[CH:24][C:23]([O:26][CH2:27][CH2:28][O:29]CC4C=CC=CC=4)=[CH:22][C:21]=3[O:37][CH3:38])[N:11]=2)[CH2:6][CH2:5]1)[CH3:3]>CO.[Pd]>[CH2:2]([N:4]1[CH2:9][CH2:8][N:7]([C:10]2[C:19]3[C:14](=[CH:15][CH:16]=[CH:17][CH:18]=3)[CH:13]=[C:12]([C:20]3[CH:25]=[CH:24][C:23]([O:26][CH2:27][CH2:28][OH:29])=[CH:22][C:21]=3[O:37][CH3:38])[N:11]=2)[CH2:6][CH2:5]1)[CH3:3]참가 물질
4
실험 절차
1-(4-Ethylpiperazin-1-yl)-3-[4-(2-benzyloxyethoxy)-2-methoxyphenyl]isoquinoline hydrochloride (0.10 g) was dissolved in methanol (20 ml), followed by the hydrogenation in the presence of 10% palladium/carbon catalyst (0.03 g) at room temperature for 6 hr. The catalyst was filtered off. The resulting solution was washed with methanol, and then the filtrate was evaporated. The resulting residue was crystallized from ethanol/ether, to give the title compound (0.04 g) as a yellow powder.